Shicheng Guo
Dake Zhang
Hu Wang
Qin An
Guangchuang Yu
Junwei Han
Chunjie Jiang
Jianfeng Huang- 1Department of Medical Genetics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States
- 2Key Laboratory of Biomechanics and Mechanobiology, Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, Beihang University, Beijing, China
- 3Institute of Cell Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, United States
- 4Salk Institute for Biological Studies, La Jolla, CA, United States
- 5Department of Bioinformatics, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
- 6College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China
- 7Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Editorial on the Research Topic
Computational and systematic analysis of multi-omics data for drug discovery and development
Introduction
The application of computational analysis in drug discovery is a promising strategy that is accelerating not only the discovery of novel therapeutic targets but also the development of drugs with greater efficacy in disease treatment. Recently, thanks to a tremendous increase in the availability of bioactive macromolecules, advances in understanding of interactions among small molecules, and advances in technologies for computer-aided antibody design, the applicability of computational analysis has been broadly extended to cover nearly every stage in the process of drug discovery and development. This includes identification and validation of the target of interest, lead discovery, assay optimization, preclinical evaluation, and clinical development (1–5). Computational drug discovery methods have evolved significantly over the past decades. Progress in molecular docking, pharmacophore modeling, mapping, de novo design, calculation of molecular similarity, and sequence-based virtual screening has enabled quicker, cheaper development of more effective solutions to address fundamental and clinical challenges. Recent advances achieved with the assistance of deep learning methods, as used by AlphaFold (6) and Rosetta (7) in protein structure prediction, constitute another perfect example of how computational solutions can influence drug development strategies. Moreover, computational immunology scientists spent only 6 months developing novel coronavirus vaccines after the first strain was identified. Finally, computational approaches have also been employed to facilitate neoantigen identification (8) and to support personalized cancer immunotherapy in the development of therapeutic cancer vaccines (9–11).
Overview of articles in this Research Topic
In collating this special issue, we have critically reviewed multiple interesting studies applying computational solutions in diverse translational scenarios, ranging from tumor management to antiviral treatment. These studies span a wide range of research fields, including cancer subtype identification via multi-omics, screening of peptidomimetic inhibitors of the NS2B–NS3 protease of the Zika virus, rapid virtual screening of drug compounds from large molecule libraries using the MO-MEMES method, in silico screening for SARS-CoV-2 protease inhibitors, in silico prediction of cell states and synthetic lethality in cancer using a metabolic network model, and identification of universal tumor markers through pan-cancer analysis.
Lung cancer is by far the leading cause of cancer-related mortality, accounting for almost 25% of all cancer deaths. Tumor heterogeneity, at both the individual and the population levels, is one of the most important findings that has been discovered in recent decades. Identification of disease-specific tumor subtypes has become an urgent priority for precision medicine in the cancer domain. Ruan et al. performed a comprehensive bioinformatics analysis and provide a practical workflow that integrates multi-omics data to identify heterogeneity in lung cancer and cancer subtypes. This study identifies four molecular subtypes, and these findings provide new insight into lung cancer subtypes and potential clinical treatment strategies to guide personalized management. The computational analytic workflow has been deposited in GitHub (https://github.com/ruan2ruan/Multi-omics-Analysis-of-LUAD).
The Zika virus (ZIKV) can cause serious birth defects and brain damage during pregnancy. As a rising public health emergency in recent years, ZIKV infection has attracted international concern. Unfortunately, there is currently neither a cure nor a vaccine for its management. An attractive therapeutic target is NS2B–NS3 protease, which plays an indispensable role in processing the ZIKV polyprotein. Polypeptides can inhibit the functions of target viral proteins, enabling the development of novel antiviral therapeutics (12–15). Using simulations of molecular dynamics, Pant et al. efficiently designed hexapeptides to occupy substrate-binding sites of the protease as novel antiviral candidates against ZIKV.
COVID-19 has become one of the greatest public health challenges; to meet the vast unmet need for COVID-19 medications, Johnson et al. applied a series of computational methods to screen potential small molecular inhibitors from 168 candidate compounds targeting SARS-CoV-2 protease. This strategy combined molecular docking, binding free energy calculations, pharmacophore modeling, induced-fit docking, simulation of molecular dynamics, and ADMET predictions. Additionally, it can easily be applied to other drug targets and larger candidate molecule pools. This study provides a good example of how in silico screening could identify potential candidate drugs for further development.
Evaluating the best candidates in a drug library requires comprehensive assessment of multiple aspects of these candidates. Mehta et al. proposed a Multi-Objective MEnhanced MolEcular Screening (MO-MEMES) framework, a machine learning-based framework for identifying the top hits in a drug library based on multiple properties. The framework uses multi-objective Bayesian optimization to identify molecules that have desirable properties on multiple variables, such as synthetic accessibility score, octanol–water partition coefficient, and binding affinity. This molecular docking framework requires only moderate computational resources to efficiently discover more than 90% of the eligible molecules, making it feasible to identify the best candidates even in large drug libraries. With simple adjustments of the parameters and scoring rules, this method can easily be applied to various other problems.
Metabolic differences are among the more important aspects of tumor phenotypes. Gao et al. integrated metabolic tasks into a multi-objective genome-scale metabolic network model. This model predicted cell states after gene knockout with higher accuracy than a conventional biomass maximization model. The predicted potential single drug targets could potentially be used as biomarkers or become drug design targets. The authors additionally implemented the same multi-objective genome-scale metabolic network model in the prediction of synthetic lethal target pairs of the basal and luminal B subtypes of breast cancer. Through analysis of the predicted synthetic lethal targets, they found that mitochondrial enzymes are potential targets for drug combinations.
Not only can the identification of pan-cancer biomarkers reveal the common molecular mechanisms in tumor development, but such biomarkers also have great potential for use in the clinical diagnosis and treatment of tumors. A comprehensive comparison using indicators widely employed in clinical settings is a direct and inevitable strategy for their evaluation. The set of various indicators relating to tumors is now increasingly complex, including such indicators as immunohistochemical staining results, DNA methylation, gene expression levels, immune response biomarkers, variation in patient survival rates, and so on. Xu et al. propose that the application of machine learning methods may result in better predictive performance in evaluating the roles of chromobox protein homolog 3 in 33 human tumors, while the interpretation of interactions between factors in the model may also pose greater challenges.
Conclusion
In the near future, it can be expected that the computational and systematic analysis of multi-omics data will continue to play a crucial role in the identification of new therapeutic targets and facilitation of the development of new drugs. With the increasing availability of large amounts of multi-omics data, machine learning and artificial intelligence will likely become more widely used to analyze this data and to identify patterns and relationships that would be difficult to detect through conventional tools and analyses. This will enable a more comprehensive understanding of the underlying biology of diseases and the identification of new drug targets. Additionally, the integration of data from multiple sources, such as genomics, proteomics, transcriptomics, and metabolomics, will provide a more complete and detailed picture of particular disease states and aid in the identification of new drug targets. Furthermore, application of a systems biology approach, in which the interactions between different components of the cell, including proteins, RNA, and metabolites, are studied in a holistic manner, is expected to grow in popularity. This approach aims to understand the complex interactions between different components of the cell and how they contribute to the development of diseases. Such an understanding will help in the identification of new drug targets that may be more effective than traditional targets, and this will also help researchers to understand the underlying mechanisms of resistance to existing drugs. In addition, the use of in silico techniques, such as virtual screening, molecular docking, and simulations of molecular dynamics, will continue to play a major role in the identification of new drugs. These techniques allow for rapid screening of large numbers of compounds, reducing the need for expensive and time-consuming in vitro and in vivo assays.
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Selevsek N, Caiment F, Nudischer R, Gmuender H, Agarkova I, Atkinson FL, et al. Network integration and modelling of dynamic drug responses at multi-omics levels. Commun Biol. (2020) 3:573. doi: 10.1038/s42003-020-01302-8
2. Jung HD, Sung YJ, Kim HU. Omics and computational modeling approaches for the effective treatment of drug-resistant cancer cells. Front Genet. (2021) 12:742902. doi: 10.3389/fgene.2021.742902
3. Ma P, Yue L, Zhang S, Hao D, Wu Z, Xu L, et al. Target RNA modification for epigenetic drug repositioning in neuroblastoma: computational omics proximity between repurposing drug and disease. Aging (Albany NY). (2020) 12:19022–44. doi: 10.18632/aging.103671
4. Tayara H, Abdelbaky I, To Chong K. Recent omics-based computational methods for COVID-19 drug discovery and repurposing. Brief Bioinform. (2021) 22:bbab339. doi: 10.1093/bib/bbab339
5. Yuan R, Chen S, Wang Y. Computational prediction of drug responses in cancer cell lines from cancer omics and detection of drug effectiveness related methylation sites. Front Genet. (2020) 11:917. doi: 10.3389/fgene.2020.00917
6. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. (2021) 596:583–9. doi: 10.1038/s41586-021-03819-2
7. Rohl CA, Strauss CE, Misura KM, Baker D. Protein structure prediction using Rosetta. Methods Enzymol. (2004) 383:66–93. doi: 10.1016/S0076-6879(04)83004-0
8. Rubinsteyn A, Kodysh J, Hodes I, Mondet S, Aksoy BA, Finnigan JP, et al. Computational pipeline for the PGV-001 neoantigen vaccine trial. Front Immunol. (2017) 8:1807. doi: 10.3389/fimmu.2017.01807
9. Rieder D, Fotakis G, Ausserhofer M, Rene G, Paster W, Trajanoski Z, et al. nextNEOpi: a comprehensive pipeline for computational neoantigen prediction. Bioinformatics. (2021) 38:1131–2. doi: 10.1093/bioinformatics/btab759
10. Hundal J, Miller CA, Griffith M, Griffith OL, Walker J, Kiwala S, et al. Cancer immunogenomics: computational neoantigen identification and vaccine design. Cold Spring Harb Symp Quant Biol. (2016) 81:105–11. doi: 10.1101/sqb.2016.81.030726
11. Kodysh J, Rubinsteyn A. OpenVax: an open-source computational pipeline for cancer neoantigen prediction. Methods Mol Biol. (2020) 2120:147–60. doi: 10.1007/978-1-0716-0327-7_10
12. Lucchese G, Stufano A, Trost B, Kusalik A, Kanduc D. Peptidology: short amino acid modules in cell biology and immunology. Amino Acids. (2007) 33:703–7. doi: 10.1007/s00726-006-0458-z
13. Conlon JM, Mechkarska M, Lukic ML, Flatt PR. Potential therapeutic applications of multifunctional host-defense peptides from frog skin as anti-cancer, anti-viral, immunomodulatory, and anti-diabetic agents. Peptides. (2014) 57:67–77. doi: 10.1016/j.peptides.2014.04.019
14. Liu H, Zeng F, Zhang M, Huang F, Wang J, Guo J, et al. Emerging landscape of cell penetrating peptide in reprogramming and gene editing. J Control Release. (2016) 226:124–37. doi: 10.1016/j.jconrel.2016.02.002
Keywords: drug discovery, computational biology, bioinformatics, multi-omics, drug development, machine learning, in silico
Citation: Guo S, Zhang D, Wang H, An Q, Yu G, Han J, Jiang C and Huang J (2023) Editorial: Computational and systematic analysis of multi-omics data for drug discovery and development. Front. Med. 10:1146896. doi: 10.3389/fmed.2023.1146896
Received: 18 January 2023; Accepted: 30 January 2023;
Published: 21 February 2023.
Edited and reviewed by: Victoria Bunik, Lomonosov Moscow State University, Russia
Copyright © 2023 Guo, Zhang, Wang, An, Yu, Han, Jiang and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shicheng Guo, 
shihcheng.guo@gmail.com